CLINICAL APPLICATIONS & FURTHER READING
Revita , scientific and clinical evidence
Revita is an intact human placental membrane allograft that preserves all layers of the biologic tissue and maintains the physiologic 3D architecture of the natural barrier membrane.
Intact Human Placental Membrane vs. Dehydrated Competitor
Revita preserves all three layers of the amniotic membrane architecture.
Unprocessed placental membrane
Revita preservation of 3D architecture
Revita provides the complete intact human placental membrane that is the physiologic tissue carrier naturally found in the body.
This complete membrane containing amnion, intermediate layer and chorion retains many of the cytokines and growth factors the body uses to heal, protect and grow tissues.
CLINICAL APPLICATIONS INCLUDE:
Venous / Arterial Ulcers
PRESERVATION OF THE INTERMEDIATE LAYER
The amniotic intermediate layer is a vital part of the membrane barrier present between the amnion and chorion layers
THE INTERMEDIATE LAYER:
Acts as a cushion
Contains Hyaluronic Acid (HA) + Collagen
Contains growth factors
Contains Glycosaminoglycans and Proteoglycans
CASE STUDY - Revita Clinical Application: Challenging Chronic Wound
Day 0 Wound
Day 0 Application
The patient in this case study was selected to evaluate this exceptional product capacity in a notably challenging clinical application. The patient, an elderly woman with multiple comorbidities and existing amputations, presented with a deep venous leg ulcer that consistently failed other treatments. Her case is presented here.
Initial Patient Evaluation and Product Application: Day 0
87-year-old female presented with a severe venous leg ulcer (VLU) on her lower right leg measuring 11 cm in length and 4 cm in width with exposed tendon and heavy exudate of purulent consistency. Conservative therapies were previously attempted for months without success.
The patient had a history of diabetes and smoking, and all toes had previously been amputated. She also reported a high pain level of 8 on a Visual Analog Scale (VAS) of 1 to 10 at the site of the VLU.
At the time of initial evaluation, the wound was cleaned and five Revita allografts were used to cover the wound.
Standard facility protocol for tissue application was followed, including placement of a non-adherent hydrogel for protection. Clinicians rated the ease of Revita application as excellent.
Follow Up: Day 27
The wound was cleaned, debrided, and clinicians re-applied five Revita allografts. Clinicians rated the ease of Revita application as excellent.
Follow Up: Day 41
Clinicians noted “good results” with healthy tissue developing around the previously exposed tendon. The wound was cleaned, debrided, and clinicians re-applied four Revita allografts.
Final Treatment: Day 62
Clinicians noted a “considerable improvement” with low exudate levels and healthy tissue development and reapplied three Revita allografts to continue treatment.
Wound continued to progress through to closure with “incredible results” noted by the clinicians.
REVITA SCIENTIFIC AND CLINICAL COMPENDIUM
- Stimlabs LLC
BIBLIOGRAPHY OF AMNIOTIC MEMBRANE TECHNOLOGY_2016 - Stimlabs LLC
REVITA A DERMATOLOGICAL EXCISION DEFECT CASE REPORT - Dr Callaway
CLINICAL LITERATURE REVIEW - Tony Parker, PhD
THE USE OF A REVITA ALLOGRAFT FOR WOUND BED PREPARATION IN A TRAUMA INDUCED WOUND - Dr Sharif
Our new Brisbane based advanced manufacturing facility is licensed by the TGA to manufacture Revita for clinical use in Australia.
(Licence # MI-2018-LI-13190-1)
Revita is registered on the Australian Register of Therapeutic Goods (ARTG Entry # 350670)